ArticleFood science & nutrition2025
Screening of Theaflavins That Inhibit Proliferation of Nasopharyngeal Carcinoma Cells Through Metabolomics Approaches.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances regarding physiological functions and mechanisms of theaflavin‑3,3'‑digallate (Review).Molecular medicine reports · 2026Review
- Screening of Theaflavins That Inhibit Proliferation of Nasopharyngeal Carcinoma Cells Through Metabolomics Approaches.Food science & nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To study the inhibitory mechanism of theaflavins on nasopharyngeal carcinoma cells to define a solid Chinese herbal antitumor remedy through metabolomics approaches. Various concentrations of theaflavin-3,3'-digallate (TF3) were examined for their effects on proliferation, migration, invasion, and apoptosis of nasopharyngeal carcinoma (NPC) cells by CCK-8, colony-forming assay, wound healing assay, trans-well migration assay, and Hoechst staining assay. Moreover, metabolomics analysis along with UHPLC-Q-TOF mass spectrometry and UHPLC-Q-Exactive Orbitrap mass spectroscopic analyses were also performed. (1) The CCK-8 assay results highlighted the activity of CNE-2 cells exposed to TF3 significantly declined in a concentration-dependent way. (2) The colony formation assay elucidated TF3 inhibitory effects on the colony formation and proliferation of CNE-2 cells and C666-1 cells. The higher the concentration of TF3, the more obvious inhibition in cell proliferation was seen. (3) The scratch test results also confirmed the migration ability of CNE-2 and C666-1 cells following the treatment of TF3. By increasing the concentration of TF3, more significant inhibition in the migration and invasion of cancer cells has been observed. (4) Hoechst staining further confirmed that TF3 could induce apoptosis in both of these cancer cell lines in a dose-dependent way. Metabolomics studies generated about 584 metabolic products of significant alterations in tea polyphenol-treated NPC cells. Multivariate analyses (PCA, PLS-DA, OPLS-DA) help establish precise group separation and model reliability, while differential metabolites were mainly enriched in ABC transporter and amino acid biosynthesis pathways. These findings suggest that tea polyphenols modulate key metabolic networks associated with cancer cell proliferation. TF3 has significantly declined proliferation, migration, and NPC cell invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.